Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29230313 | 1.00 | ALDH1A1 (0.33) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| SCHEMBL29230314 | 1.00 | ALDH1A1 (0.33) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| Hydrochloric Acid SCHEMBL29230339 | 0.97 | ALDH1A1 (0.32) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| Hydrochloric Acid SCHEMBL29230337 | 0.97 | ALDH1A1 (0.32) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| SCHEMBL4745235 | 0.79 | ALDH1A1 (0.31) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL13661686 | 0.78 | — | — | |
| SCHEMBL26606619 | 0.78 | — | — | |
| SCHEMBL8703006 | 0.77 | TP53 (0.33) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| SCHEMBL737459 | 0.76 | TDP1 (0.38) | — | |
| SCHEMBL20811652 | 0.76 | ALDH1A1 (0.32) | ALDH1A1MAPTPTGS1SLC7A5TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20060009392-A1 | Salt with physiologically tolerated acid; resistant to enzymatic degradation; oral administration | ABBOTT GMBH & CO., KG. (US) | 2006-01-12 | — | — | US | disclosed |
| EP-1593686-A1 | Antineoplastic peptides | Abbott GmbH & Co. KG (DE) | 2005-11-09 | — | — | EP | disclosed |
| EP-0866800-B1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO KG (DE) | 2004-09-22 | — | — | EP | disclosed |
| EP-0981358-B1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AG (DE) | 2003-05-28 | — | — | EP | disclosed |
| EP-0871656-B1 | DOLASTATIN DERIVATIVES, THEIR PREPARATION AND USE | ABBOTT GMBH & CO KG (DE) | 2002-09-25 | — | — | EP | disclosed |
| EP-0832104-B1 | DOLASTATIN DERIVATIVES, THEIR PREPARATION AND USE | ABBOTT GMBH & CO KG (DE) | 2002-09-04 | — | — | EP | disclosed |
| EP-0871656-A1 | NOVEL DOLASTATIN DERIVATIVES, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-21 | — | — | EP | disclosed |
| EP-0866800-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-30 | — | — | EP | disclosed |
| WO-1998040092-A1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
| EP-0642530-B1 | DERIVATIVES OF DOLASTATIN | BASF AG (DE) | 1998-08-12 | — | — | EP | disclosed |
| EP-0842190-A1 | PROCESS FOR PRODUCING DOLASTATIN 15 AND INTERMEDIATES THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
| US-5741892-A | Pentapeptides as antitumor agents | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-21 | — | — | US | disclosed |
| WO-1998004581-A1 | DOLASTATIN PENTAPEPTIDE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-05 | — | — | WO | disclosed |
| WO-1997022621-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-26 | — | — | WO | disclosed |
| WO-1997005162-A1 | PROCESS FOR PRODUCING DOLASTATIN 15 AND INTERMEDIATES THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 1997-02-13 | — | — | WO | disclosed |
| WO-1996040752-A1 | NOVEL DOLASTATIN DERIVATIVES, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234205-A1 | Antineoplastic peptides | BCL2A1, ETF1, BAK1 | ALDH1A1 4381/4885MAPT 4864/4885PTGS1 1831/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | ALDH1A1 1287/4885MAPT 2094/4885PTGS1 3143/4885 |
| US-20060009392-A1 | Salt with physiologically tolerated acid; resistant to enzymatic degradation; oral administration | CTRB1, CTRB2, BCKDK | ALDH1A1 2715/4885MAPT 4865/4885PTGS1 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.